J Wave Syndrome Summit 2022 in Japan

座 長 清水 渉 (日本医科大学大学院医学研究科 循環器内科学分野)
Charles Antzelevitch (The Lankenau Institute for Medical Research)

J wave syndrome (JWS) has been originally proposed by Antzelevitch and Yan in 2010 as a clinical entity of arrhythmia, which is linked to abnormalities in the manifestation of the J wave, including early repolarization syndrome, Brugada syndrome, or arrhythmias associated with hypothermia and some acute phase of ST-segment elevation myocardial infarction. Over the last decade, the pathophysiology of arrhythmogenic substrate, molecular mechanism, diagnosis, risk stratification, management and therapy of JWS have been evaluated and debated. What is important is to make use of the accumulated knowledge of JWS for the last decade for better understanding, management and optimal pharmacological and non-pharmacological treatments of each disease. In this J Wave Syndrome Summit 2022 in Japan, two distinguished speakers are invited from overseas to give us their keynote lectures from the basic and clinical point of view. Following the two keynote lectures, Japanese expert physicians and researchers are welcome to present their latest clinical and experimental data and to provide a comprehensive discussion for better understanding, management and optimal treatments of JWS.